{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:29:23Z","timestamp":1786606163563,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Abbott Products Operations AG Switzerland."},{"DOI":"10.13039\/501100001791","name":"Griffith University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001791","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Biologic treatments demonstrate long-term clinical benefits for patients with osteoporosis, but their cost is prohibitive, and access can be limited, particularly in low-income countries. This analysis determined the cost impact of introducing biosimilar denosumab for the treatment of osteoporosis in Malaysia and Thailand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A budget impact model was developed to compare the cost of treating female patients aged\u2009\u2265\u200950\u00a0years with osteoporosis with biosimilar versus reference denosumab (60\u00a0mg\/mL every 6\u00a0months) from a healthcare payer perspective in Malaysia and Thailand over 5-years. Model inputs included previously published, country-specific prevalence, incidence, mortality, and treatment data, supplemented by expert clinical advice where evidence was limited. Drug acquisition cost was assumed to cost 25% less than the reference product. Further assumptions included no change in osteoporosis incidence and mortality over the time horizon and consistent condition-related costs across both scenarios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over 5\u00a0years, treatment with the reference denosumab was estimated to cost MYR\u2009~\u2009864 million (USD\u2009~\u2009217 million) in Malaysia and THB\u2009~\u2009179.5 billion (USD\u2009~\u20095.2 billion) in Thailand. Biosimilar denosumab was estimated to cost MYR\u2009~\u2009648 million (USD\u2009~\u2009162 million) and THB\u2009~\u2009134.6 billion (USD\u2009~\u20093.9 billion), resulting in potential savings of MYR\u2009~\u2009216 million (USD\u2009~\u200954 million) and THB 44.8 billion (USD\u2009~\u20091.3 billion), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The introduction of biosimilar denosumab in Malaysia and Thailand could yield significant cost savings and enhance access to biologic therapies for postmenopausal women with osteoporosis. The inclusion of biosimilar denosumab in national osteoporosis management programs could lead to increased uptake, but it is not explored in this analysis and requires further consideration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-026-01752-3","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:55:59Z","timestamp":1786604159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osteoporosis treatment with biosimilars in Malaysia and Thailand: a budget impact analysis"],"prefix":"10.1007","volume":"21","author":[{"given":"Linda","family":"Siachalinga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Downes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Solev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanut","family":"Valleenukul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"12","key":"1752_CR1","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s00198-005-2003-4","volume":"16","author":"PS Lim","year":"2005","unstructured":"Lim PS et al (2005) Bone health in urban midlife Malaysian women: risk factors and prevention. Osteoporos Int 16(12):2069\u20132079","journal-title":"Osteoporos Int"},{"issue":"1","key":"1752_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-021-02821-8","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari N et al (2021) Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16(1):669","journal-title":"J Orthop Surg Res"},{"issue":"2","key":"1752_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.afos.2023.05.002","volume":"9","author":"N Charoenngam","year":"2023","unstructured":"Charoenngam N, Pongchaiyakul C (2023) Current issues in evaluation and management of osteoporosis in Thailand. Osteoporos Sarcopenia 9(2):53\u201359","journal-title":"Osteoporos Sarcopenia"},{"issue":"1","key":"1752_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00042192-200101000-00011","volume":"8","author":"KK Limpaphayom","year":"2001","unstructured":"Limpaphayom KK et al (2001) Prevalence of osteopenia and osteoporosis in Thai women. Menopause 8(1):65\u201369","journal-title":"Menopause"},{"key":"1752_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.882241","volume":"13","author":"Y Shen","year":"2022","unstructured":"Shen Y et al (2022) The global burden of osteoporosis, low bone mass, and its related fracture in 204 countries and territories, 1990\u20132019. Front Endocrinol (Lausanne) 13:882241","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1752_CR6","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s001980170135","volume":"12","author":"EM Lau","year":"2001","unstructured":"Lau EM et al (2001) The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS). Osteoporos Int 12(3):239\u2013243","journal-title":"Osteoporos Int"},{"issue":"2","key":"1752_CR7","first-page":"261","volume":"91","author":"C Pongchaiyakul","year":"2008","unstructured":"Pongchaiyakul C, Songpattanasilp T, Taechakraichana N (2008) Burden of osteoporosis in Thailand. J Med Assoc Thai 91(2):261\u2013267","journal-title":"J Med Assoc Thai"},{"issue":"1","key":"1752_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.afos.2018.03.003","volume":"4","author":"CL Cheung","year":"2018","unstructured":"Cheung CL et al (2018) An updated hip fracture projection in Asia: the Asian Federation of Osteoporosis Societies study. Osteoporos Sarcopenia 4(1):16\u201321","journal-title":"Osteoporos Sarcopenia"},{"issue":"1","key":"1752_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler DL et al (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 39(1):58\u201374","journal-title":"Adv Ther"},{"issue":"7","key":"1752_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1080\/13696998.2020.1730381","volume":"23","author":"C Pongchaiyakul","year":"2020","unstructured":"Pongchaiyakul C et al (2020) Cost-effectiveness of denosumab for high-risk postmenopausal women with osteoporosis in Thailand. J Med Econ 23(7):776\u2013785","journal-title":"J Med Econ"},{"issue":"4","key":"1752_CR11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40259-025-00727-z","volume":"39","author":"TK Kvien","year":"2025","unstructured":"Kvien TK et al (2025) Beyond cost: observations on clinical and patient benefits of biosimilars in real-world settings. BioDrugs 39(4):537\u2013553","journal-title":"BioDrugs"},{"issue":"1","key":"1752_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/20523211.2025.2526827","volume":"18","author":"A Assawamakin","year":"2025","unstructured":"Assawamakin A et al (2025) Beyond cost: a value-based framework for biosimilar procurement in emerging markets - the Thai experience. J Pharm Policy Pract 18(1):2526827","journal-title":"J Pharm Policy Pract"},{"issue":"Supplement 1","key":"1752_CR13","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ard.2025.05.858","volume":"84","author":"K Shastri","year":"2025","unstructured":"Shastri K et al (2025) POS0476 Analysing the economic impact of denosumab in the treatment of osteoporosis. Ann Rheum Dis 84(Supplement 1):698\u2013699","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1752_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8(1):136","journal-title":"Arch Osteoporos"},{"key":"1752_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fphar.2017.00314","volume":"8","author":"E Moorkens","year":"2017","unstructured":"Moorkens E et al (2017) The market of biopharmaceutical medicines: a snapshot of a diverse industrial landscape. Front Pharmacol 8:314","journal-title":"Front Pharmacol"},{"issue":"1","key":"1752_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD et al (2014) Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 17(1):5\u201314","journal-title":"Value Health"},{"key":"1752_CR17","doi-asserted-by":"crossref","unstructured":"Garrison LP Jr. et al (2013) Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health 16(5):703\u201319","DOI":"10.1016\/j.jval.2013.04.011"},{"key":"1752_CR18","unstructured":"Abbott (2025) Data on file. Denosumab biosimilar access strategy: Malaysia. Abbott Laboratories"},{"key":"1752_CR19","unstructured":"Abbott (2025) Data on file. Denosumab biosimilar access strategy: Thailand. Abbott Laboratories"},{"key":"1752_CR20","unstructured":"Abbott. Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment. 2025 September 2025]; Available from: https:\/\/www.prnewswire.com\/apac\/news-releases\/abbott-receives-regulatory-approval-for-the-first-denosumab-biosimilar-in-thailand-expanding-access-to-bone-disease-treatment-302538584.html"},{"issue":"1","key":"1752_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11657-023-01358-z","volume":"18","author":"YW Choo","year":"2023","unstructured":"Choo YW et al (2023) Budget impact of increasing uptake of denosumab for the treatment of postmenopausal osteoporosis in Malaysia. Arch Osteoporos 18(1):145","journal-title":"Arch Osteoporos"},{"key":"1752_CR22","unstructured":"OpenDOSM. Population Table: Malaysia 2025 September 2025]; Available from: https:\/\/open.dosm.gov.my\/data-catalogue\/population_malaysia"},{"key":"1752_CR23","unstructured":"Watts JJ, Abimanyi-Ochom J, Sanders KM (2013) Osteoporosis costing all Australians A new burden of diseaseanalysis \u2013 2012 to 2022, in Osteoporosis Australia. Glebe, NSW, Australia.\u00a0https:\/\/healthybonesaustralia.org.au\/wp-content\/uploads\/2022\/09\/burden-of-disease-analysis-2012-2022.pdf"},{"key":"1752_CR24","unstructured":"World Bank Group. World Bank Open Data. 2023 September 2024]; Available from: https:\/\/data.worldbank.org\/"},{"key":"1752_CR25","unstructured":"World Health Organization. Life tables: Life tables by WHO region Global. 2022; Available from: https:\/\/apps.who.int\/gho\/data\/view.searo.LIFEREGIONGLOBAL?lang=en"},{"issue":"1","key":"1752_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11657-024-01425-z","volume":"19","author":"N Charoenngam","year":"2024","unstructured":"Charoenngam N et al (2024) Trends in osteoporosis prevalence at a tertiary care referral center hospital in Northeastern Thailand: a 20-year analysis (2003\u20132022). Arch Osteoporos 19(1):64","journal-title":"Arch Osteoporos"},{"key":"1752_CR27","unstructured":"National Drug Policy Division. National Drug Information (2025) [cited 15 August 2025]; Available from https:\/\/ndi.fda.moph.go.th\/drug_detail\/index\/?rctype=1C&rcno=6200002\u00aeister=MUMgMi82MihOQik="},{"issue":"3","key":"1752_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5429","volume":"5","author":"K Feng","year":"2024","unstructured":"Feng K et al (2024) Patient out-of-pocket costs for biologic drugs after biosimilar competition. JAMA Health Forum 5(3):e235429","journal-title":"JAMA Health Forum"},{"key":"1752_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1256542","volume":"14","author":"MA Pontes","year":"2023","unstructured":"Pontes MA et al (2023) Comparative price analysis of biological medicines: disparities generated by different pricing policies. Front Pharmacol 14:1256542","journal-title":"Front Pharmacol"},{"issue":"2","key":"1752_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziad020","volume":"8","author":"A Asavamongkolkul","year":"2024","unstructured":"Asavamongkolkul A et al (2024) Prevalence of osteoporosis, sarcopenia, and high falls risk in healthy community-dwelling Thai older adults: a nationwide cross-sectional study. JBMR Plus 8(2):ziad020","journal-title":"JBMR Plus"},{"issue":"8","key":"1752_CR31","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14712598.2025.2540471","volume":"25","author":"M Aapro","year":"2025","unstructured":"Aapro M et al (2025) Biosimilars in osteoporosis treatment: focus on denosumab. Expert Opin Biol Ther 25(8):887\u2013898","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1752_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-12834-5","volume":"22","author":"NZA Mohd Hassan","year":"2022","unstructured":"Mohd Hassan NZA et al (2022) The inequalities and determinants of households\u2019 distress financing on out-off-pocket health expenditure in Malaysia. BMC Public Health 22(1):449","journal-title":"BMC Public Health"},{"issue":"6","key":"1752_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304851","volume":"19","author":"HH Chen","year":"2024","unstructured":"Chen HH, Yemeke T, Ozawa S (2024) Reduction of biologic pricing following biosimilar introduction: analysis across 57 countries and regions, 2012\u201319. PLoS ONE 19(6):e0304851","journal-title":"PLoS ONE"},{"key":"1752_CR34","unstructured":"Biosimilars Council (2025)\u00a0Biosimilar Medicines Saved $12.4 Billion in 2023. Available online: https:\/\/biosimilarscouncil.org\/news\/biosimilar-medicines-saved-12-4-billion\/. Accessed 31 Oct 2025"},{"key":"1752_CR35","unstructured":"AAM (2025)\u00a0U.S. Generic & Biosimilar Medicines Savings Report. Available online: https:\/\/accessiblemeds.org\/resources\/reports\/2025-savings-report\/.  Accessed 31 Oct 2025"},{"issue":"5","key":"1752_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s41669-024-00491-w","volume":"8","author":"SH Tan","year":"2024","unstructured":"Tan SH et al (2024) Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story. Pharmacoecon Open 8(5):679\u2013688","journal-title":"Pharmacoecon Open"},{"key":"1752_CR37","unstructured":"Association for Accessible Medicines. The U.S. Generic & Biosimilar Medicines Savings Report. 2024 September 2025]; Available from: https:\/\/accessiblemeds.org\/wp-content\/uploads\/2025\/01\/AAM-2024-Generic-Biosimilar-Medicines-Savings-Report.pdf."},{"key":"1752_CR38","doi-asserted-by":"crossref","unstructured":"Ntais C et al (2024)\u00a0Fostering healthcare system sustainability through efficient practices: Can adopting biosimilars ease the financial burden of rheumatoid arthritis? F1000Res 13:1128","DOI":"10.12688\/f1000research.156983.1"},{"issue":"5","key":"1752_CR39","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.clinthera.2016.02.023","volume":"38","author":"M Khraishi","year":"2016","unstructured":"Khraishi M et al (2016) Biosimilars: a multidisciplinary perspective. Clin Ther 38(5):1238\u20131249","journal-title":"Clin Ther"},{"issue":"1","key":"1752_CR40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13075-015-0713-3","volume":"17","author":"CS Moura","year":"2015","unstructured":"Moura CS et al (2015) Early medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study. Arthritis Res Ther 17(1):197","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1752_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s43441-024-00716-4","volume":"59","author":"KA Alnaqbi","year":"2025","unstructured":"Alnaqbi KA et al (2025) Expert consensus recommendations on a biosimilars value framework for the Gulf Cooperation Council countries. Ther Innov Regul Sci 59(1):153\u2013163","journal-title":"Ther Innov Regul Sci"},{"key":"1752_CR42","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.2147\/DDDT.S75219","volume":"9","author":"E Li","year":"2015","unstructured":"Li E et al (2015) Development of biosimilars in an era of oncologic drug shortages. Drug Des Devel Ther 9:3247\u20133255","journal-title":"Drug Des Devel Ther"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01752-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01752-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01752-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T06:56:13Z","timestamp":1786604173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-026-01752-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1752"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01752-3","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Linda Siachalinga, Hansoo Kim and Arun Jones are researchers employed at Griffith University\u2019s Centre for Applied Health Economics when carried out this research, which was funded by Abbott Products Operations AG. Kyoo Kim and Igor Solev are employees of Abbott Products Operations AG, Switzerland. Kenneth Lee has received\u00a0remuneration\u00a0for speaking engagements from AbbVie, GSK, Novartis,\u00a0Pfizer, Roche and ZeroRange. He also received research grant support\u00a0from Eisai, Johnson & Johnson, Merck, Mitsubishi, MSD, Novartis, Pfizer, Servier, Takeda and Zuellig. This research was funded by Abbott Products Operation AG. Thanut Valleenukul declares no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"117"}}